Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: Results of randomised, placebo-controlled trials

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 95-100

  Sieper, Joachim ^a   Porter Brown, Benjamin ^b   Thompson, Liz ^b   Harari, Olivier ^b   Dougados, Maxime ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR; PLACEBO; TOCILIZUMAB;

ADULT; ALLERGIC REACTION; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT;

ANKYLOSING SPONDYLITIS; INFLAMMATION; TREATMENT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84889684742     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203559     Document Type: Article

References (44)

1. Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010;6:399-405.
2. Rosenbaum J, Chandran V. Management of comorbidities in ankylosing spondylitis. Am J Med Sci 2012;343:364-6.
3. Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al. Arthritis Rheum 2005;52:4048-9.
4. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
5. Zochling J, Bohl-Buhler MH, Baraliakos X, et al. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis: a population-based survey. Clin Rheumatol 2006;25:794-800. (Pubitemid 44473141)
6. Roychowdhury B, Bintley-Bagot S, Bulgen DY, et al. Is methotrexate effective in ankylosing spondylitis? Rheumatology 2002;41:1330-2.
7. Altan L, Bingol U, Karakoc Y, et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9. (Pubitemid 32980336)
8. Braun J, Baraliakos X, Godolias G, et al. Therapy of ankylosing spondylitis: a review. Part I: conventional medical treatment and surgical therapy. Scand J Rheumatol 2005;34:97-108. (Pubitemid 40694828)
9. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
10. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93. (Pubitemid 34304258)
11. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75. (Pubitemid 36682375)
12. Van Der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.
13. Van Der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)
14. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6. (Pubitemid 37409337)
15. Van Der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91. (Pubitemid 40216323)
16. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-8.
17. Van Der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
18. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31. (Pubitemid 24324807)
19. Gratacos J, Collado A, Pons F, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a follow-up study. Arthritis Rheum 1999;42:2319-24. (Pubitemid 30333411)
20. Falkenbach A, Herold M. In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 1998;18:103-6. (Pubitemid 28505331)
21. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-15. (Pubitemid 46020247)
22. Tutuncu ZN, Bilgie A, Kennedy LG, et al. Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 1994;53:425-6. (Pubitemid 24198933)
23. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-17. (Pubitemid 351498433)
24. Visvanathan S, Van Der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:175-82.
25. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731-40. (Pubitemid 41116745)
26. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
27. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
28. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
29. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
30. Kremer JM, Blanco R, Brzosko S, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
31. Actemra® (tocilizumab) injection for intravenous infusion [ prescribing information]. South San Francisco, CA: Genentech, Inc.; October 2012.
32. RoACTEMRA 20 mg/ml concentrate for solution for infusion [ prescribing information]. Welwyn Garden City, UK: Roche Registration Limited; 2012.
33. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
34. Brulhart L, Nissen MJ, Chevallier P, et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010;77:625-6.
35. Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010;69:2217-18.
36. Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Modern Rheumatol 2011;21:436-9.
37. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol 2011;38:1527.
38. Dudler J, Aubry-Rozier B. Tocilizumab in axial spondylarthropathies: about 18 cases [abstract]. Ann Rheum Dis 2011;70(Suppl 3):128.
39. Del Castillo Piñol N, Gossec L, Sparsa L, et al. Tocilizumab for treatment of refractory spondyloarthritis: report of 5 patients [abstract]. Ann Rheum Dis 2011;70 (Suppl 3):343.
40. Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64:296-8. (Pubitemid 40193630)
41. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108-10.
42. Park MC, Lee SW, Choi ST, et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 2007;36:101-6.
43. Sieper J, Inman RD, Badalamente S, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized, double-blind, placebo-controlled, international study (ALIGN) [abstract]. Ann Rheum Dis 2012;71 (Suppl 3):111.
44. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:1-13.